Insulin resistance due to statin therapy: a potential contributor to the negation of statin-induced beneficial effects on cardiac remodelling in heart failure?

摘要

In their recently published article (a sub-study of UNIVERSE), Ashton E et al. explored potential adverse effects of rosuvastatin including effects on plasma coenzym Q10 (CoQ.) levels and collagen turnover in patients with chronic heart failure (CHF) [1], and tried to explain why high dose rosuvastatin failed to improve cardiac remodelling in CHF in the UNIVERSE study [2]. I agree with the authors that increased collagen turnover and decreased plasma CoQ. levels due to rosuvastatin therapy might have negatively influenced cardiac remodelling [1]. However, other factors including decreased insulin sensitivity may also play a role in the negation of rosuvastatin's beneficial effects on cardiac remodelling in heart failure (HF).